Search
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesValspodar
go.drugbank.com/drugs/DB11869InvestigationalValspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEpanolol
go.drugbank.com/drugs/DB13757ExperimentalEpanolol is an beta blocker.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesDexrabeprazole
go.drugbank.com/drugs/DB13762InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesCaroverine
go.drugbank.com/drugs/DB13835InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCloprednol
go.drugbank.com/drugs/DB13843InvestigationalCloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersMeningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Candesartan
go.drugbank.com/drugs/DB13919InvestigationalCandesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
Synonyms: 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acidCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates